HYPOSIALYLATION DISORDERS
    1.
    发明申请
    HYPOSIALYLATION DISORDERS 有权
    高血压病

    公开(公告)号:US20140271615A1

    公开(公告)日:2014-09-18

    申请号:US14208570

    申请日:2014-03-13

    IPC分类号: G01N33/53

    摘要: Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder. In additional embodiments, these methods can be used to determine the lowest effective dosage of the therapeutic agent of use to treat the subject.

    摘要翻译: 公开了用于诊断腰酸症的方法。 还公开了用于确定治疗剂用于治疗受试者中的唾液酸化障碍的有效性的方法。 这些方法包括测量单唾液酸化Thomsen-Friedenreich(ST)抗原的量并测量生物样品中的非唾液酸化Thomsen-Friedenreich抗原(T)的量,例如来自受试者的血清或血浆样品,并测定 T到ST T与单唾液酸化ST的比例约为0.06或更高,可诊断出唾液酸化失调,或表明治疗剂对于治疗唾液酸化失调无效。 在其它实施方案中,T与ST的比值小于约0.06表示治疗剂对于治疗低唾液酸化障碍是有效的,或者受试者不具有低唾液酸化障碍。 在另外的实施方案中,这些方法可用于确定用于治疗受试者的治疗剂的最低有效剂量。